SCHEMBL13627919

SCHEMBL13627919

Cc1ccc2c(c1)/C(=N/O)C(=O)N2Cc1ccc(F)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.53
HSP90AA1 P07900 1/20 0.53
MAPT P10636 3/20 0.48
TP53 P04637 3/20 0.48
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA9 Q16790 1/20 0.47
ALDH1A1 P00352 5/20 0.46
LMNA P02545 2/20 0.46
POLB P06746 1/20 0.46
CHRM5 P08912 1/20 0.45
HPGD P15428 1/20 0.45
UBE2N P61088 1/20 0.45
ATM Q13315 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
ALDH3A1 P30838 4/20 0.44
CASP3 P42574 1/20 0.43
CASP7 P55210 1/20 0.43
TRPA1 O75762 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13627940 0.93 CHRM5 (0.51) ACHEHSP90AA1MAPTTP53CA12
SCHEMBL13627921 0.92 ACHE (0.58) ACHEHSP90AA1MAPTTP53CA12
SCHEMBL13627937 0.90 CHRM5 (0.55) ACHECA12CA1CA2CA9
SCHEMBL13627889 0.89 ACHE (0.54) ACHEHSP90AA1MAPTTP53CA12
SCHEMBL13627917 0.87 ACHE (0.52) ACHEHSP90AA1MAPTTP53CA12
SCHEMBL13627923 0.87 UBE2N (0.52) ACHEHSP90AA1MAPTTP53CA12
SCHEMBL13627928 0.86 ALDH3A1 (0.51) CA12CA1CA2CA9ALDH1A1
SCHEMBL13627901 0.85 ACHE (0.58) ACHECA12CA1CA2CA9
SCHEMBL13627948 0.84 TRPA1 (0.48) MAPTCA12CA1CA2CA9
SCHEMBL13627931 0.84 CA1 (0.56) ACHEHSP90AA1MAPTTP53CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
EP-1175399-B1 INHIBITORS OF C-JUN N-TERMINAL KINASES (JNK) VERTEX PHARMA (US) 2009-03-11 EP disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) MAP3K1, JUN, MAP3K7 ACHE 4079/4885HSP90AA1 714/4885MAPT 1666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.